Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis

P Kellokumpu-Lehtinen, H Joensuu, T Joensuu, P Hervonen, T Nyandoto, T Luukkaala, T Hemminki, R Asola, M Lukkaa, I Lehtinen

    Research output: Contribution to journalArticleScientific

    Original languageEnglish
    JournalEUR J CANCER
    Volume5
    Issue numbersuppl 285
    Publication statusPublished - 2007
    Publication typeB1 Article in a scientific magazine

    Cite this